K-numberK243144
Device nameX100/X100HT with Full Field Peripheral Blood Smear (PBS) Application
ApplicantScopio Labs , Ltd.
Product codeJOY
Device classClass II
Decision dateJun 27, 2025
DecisionSubstantially Equivalent
Regulation864.5260
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The X100/X100HT with Full Field Peripheral Blood Smear (PBS) Application is a digital cell morphology system that automatically locates and displays high-resolution images of white blood cells, red blood cells, and platelets from fixed and stained blood smears. It assists qualified technologists in conducting WBC differentials, RBC morphology evaluation, and platelet estimates for in vitro diagnostic use.

Technological characteristics

The device uses fully automated scanning and image acquisition to capture multiple images under varying illumination conditions, reconstructing 100X magnification images without immersion oil. The modification adds decision support system (DSS) features: system-suggested RBC morphological pre-gradings shown with dotted lines around selection boxes, and system-suggested platelet clump detection indicators. Critically, users must actively confirm or adjust all suggestions; the system does not auto-populate final results.

Test standards cited

CLSI EP05-A3 (Evaluation of Precision of Quantitative Measurement Procedures) was used for repeatability and reproducibility studies. FDA's Guidance for the Content of Premarket Submission for Software Contained in Medical Devices (June 14, 2023) was applied for software verification and validation testing at the Basic Documentation Level.

Substantial equivalence argument

The modified device is substantially equivalent because it retains identical intended use, intended user population, sample type, and core analysis techniques as the predicate (K201301, K220013). The sole technological difference—addition of DSS suggestions for RBC morphology and platelet clumping—does not change safety or effectiveness since users retain full manual control and must actively confirm all grading decisions, preserving the cleared workflow. Method comparison testing on 1200 slides and precision studies demonstrated performance meeting pre-defined acceptance criteria across all RBC and platelet parameters.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →